Literature DB >> 1445982

Antibiotic-induced release of endotoxin: a reappraisal.

J C Hurley1.   

Abstract

A three- to 20-fold increase in the total concentration of endotoxin occurs as a consequence of antibiotic action on gram-negative bacteria both in vitro and in vivo. There is considerable overlap between the effect of beta-lactam antibiotics and non-beta-lactam antibiotics. Moreover, there is an unexplained delay between the lethal activity of antibiotics and the release of endotoxin. Hence, the mechanism whereby antibiotic action leads to the release of endotoxin is unclear, and mechanisms other than bacterial lysis warrant consideration. The evidence that the release of endotoxin has clinical importance is conflicting, and the issue is unresolved. However, nonlytic release may have implications for the therapeutic efficacy of antiendotoxin immunotherapy. Although frequently cited in the context of the antibiotic-induced release of endotoxin, a number of important differences pertain to conditions, such as the Jarisch-Herxheimer reaction and the tumor lysis syndrome, for which there is clear evidence of an initial deterioration with effective therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445982     DOI: 10.1093/clind/15.5.840

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  48 in total

1.  Lysis syndrome during therapy of visceral leishmaniasis.

Authors:  E N Liberopoulos; A A Kei; M S Elisaf
Journal:  Infection       Date:  2011-10-18       Impact factor: 3.553

Review 2.  Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.

Authors:  J C Hurley
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

3.  Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteremia, clinical findings and serum cytokine pattern.

Authors:  P Engervall; M Granström; B Andersson; M Kalin; M Björkholm
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

4.  Endotoxemia as a diagnostic tool for patients with suspected bacteremia caused by gram-negative organisms: a meta-analysis of 4 decades of studies.

Authors:  James C Hurley; Piotr Nowak; Lars Öhrmalm; Charalambos Gogos; Apostolos Armaganidis; Evangelos J Giamarellos-Bourboulis
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

Review 5.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

6.  Structural correlation between lipophilicity and lipopolysaccharide-sequestering activity in spermine-sulfonamide analogs.

Authors:  Mark R Burns; Scott A Jenkins; Nicolas M Vermeulen; Rajalakshmi Balakrishna; Thuan B Nguyen; Matthew R Kimbrell; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2006-09-28       Impact factor: 2.823

Review 7.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  The anti-lipid A antibody HA-1A binds to rough gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35).

Authors:  M Tonoli; K A Davies; P J Norsworthy; J Cohen; M J Walport
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Effect of imipenem on monoclonal antibody-mediated protection against Escherichia coli O18K5.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; W Hustinx; J Schellekens; K Kraaijeveld; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.

Authors:  C A Gogos; A Skoutelis; A Lekkou; E Drosou; I Starakis; M N Marangos; H P Bassaris
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.